Abstract: A mammalian cell gene expression vector system comprising (a) an episomal maintenance system (b), a strong promoter/enhancer, (c) a protein transactivation system and (d) DNA coding for a heterologous protein. The episomal maintenance and protein transactivation systems can include sub-elements located on the same or different plasmids within the cell expression system.

Abstract: The invention concerns methods and means for facilitating the translocation of molecules through the gastrointestinal tract of mammals. In particular, the invention concerns methods for identifying antibodies, including antibody fragments, capable of translocation from the lumenal side of gastrointestinal tissue into the blood stream or into the lymphatic circulation. The invention further concerns the identification of sequences within or associated with such antibodies facilitating translocation through the gastrointestinal tract. The invention additionally concerns the use of such antibodies and sequences, or other molecules or moieties identified by using such antibodies or sequences, for facilitating oral delivery and absorption of molecules, such as biomolecules (including proteins and nucleic acids), antibodies, peptides, and non-peptide small molecules.

Abstract: A mammalian cell gene expression vector system comprising (a) an episomal maintenance system (b), a strong promoter/enhancer, (c) a protein transactivation system and (d) DNA coding for a heterologous protein. The episomal maintenance and protein transactivation systems can include sub-elements located on the same or different plasmids within the cell expression system.

Abstract: This invention describes a protein-free production process for proteins having factor VIII procoagulant activity. The process includes the derivation of stable human cell clones with high productivity for B-domain deleted Factor VIII, and (2) the adaptation of cells to grow in a medium free of plasma-derived proteins.

Abstract: This invention describes a protein-free production process for proteins having factor VIII procoagulant activity. The process includes the derivation of stable human cell clones with high productivity for B-domain deleted Factor VIII, and (2) the adaptation of cells to grow in a medium free of plasma-derived proteins.

Abstract: This invention describes a protein-free production process for proteins having factor VIII procoagulant activity. The process includes the derivation of stable human cell clones with high productivity for B-domain deleted Factor VIII, and (2) the adaptation of cells to grow in a medium free of plasma-derived proteins.